Trials / Completed
CompletedNCT00856869
Clearance of NRL972 in Patients With Cirrhosis, Nonalcoholic Steatohepatitis (NASH) and in Healthy Volunteers
A Study in Healthy Volunteers and Patients With Liver Cirrhosis and Non-Alcoholic Steatohepatitis (NASH) to Assess the Effects of Age, Gender, Chronic Liver Disease, and Prandial Effects on the Clearance of Cholyl-Lysyl-Fluorescein (NRL972) an an in-Vivo Marker of Liver Function in Man.
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Norgine · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The study was conducted to describe and compare the plasma pharmacokinetics of NRL972 administered after a standard meal and while fasted in patients with hepatic cirrhosis (Child-Turcotte-Pugh \[CTP\] class A-C), NASH, young and elderly healthy males, and young and elderly healthy females, to assess the effects of liver dysfunction, gender, age and prandial intestinal hyperaemia on the clearance of NRL972. In addition, the study was to provide information on the safety and tolerability of repeated intravenous doses of NRL972 in these populations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NRL972 | Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal |
| DRUG | NRL972 | Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal |
| DRUG | NRL972 | Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal |
| DRUG | NRL972 | Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal |
| DRUG | NRL972 | Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal |
| DRUG | NRL972 | Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal |
| DRUG | NRL972 | Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal |
Timeline
- Start date
- 2004-08-01
- Primary completion
- 2005-02-01
- Completion
- 2005-04-01
- First posted
- 2009-03-06
- Last updated
- 2009-03-06
Locations
1 site across 1 country: Bulgaria
Source: ClinicalTrials.gov record NCT00856869. Inclusion in this directory is not an endorsement.